Author

Xiangyan Chen

Institutions: University of Electronic Science and Technology of China, Sichuan Cancer Hospital, Yancheng Institute of Technology, Second Affiliated Hospital of Chengdu University of Traditional Chinese, Chengdu University of Traditional Chinese Medicine

Observed institutions: University of Electronic Science and Technology of China, Sichuan Cancer Hospital, Yancheng Institute of Technology, Second Affiliated Hospital of Chengdu University of Traditional Chinese, Chengdu University of Traditional Chinese Medicine

ORCID: 0000-0002-7135-862X

Observed ORCID: 0000-0002-7135-862X

OpenAlex ID: A5123842417

Discovery of substituted quinoxaline-2,3(1H,4H)‑dione as potent, selective, and orally bioavailable aldose reductase inhibitors targeting for diabetic complications

2026 · Zhongfei Han, Qianxi Jiang, et al. · Journal of Molecular Structure · 2

Novel hydroxyacetimidamide derivatives of quinolin-4(1H)-one as dual inhibitor targeting AKR1B1/α-glucosidase for treatment of diabetic complications: Design, synthesis and biological evaluation

2026 · Xin Hao, Xuying Wang, et al. · Journal of Molecular Structure · 1

Mechanotherapy enhances nanodrug uptake by overcoming the actin cytoskeleton damping effect

2026 · Hao Wu, Xue Shen, et al. · Proceedings of the National Academy of Sciences

The Therapeutic Potential of Berberine in Treating Diabetes and Its Complications: Molecular Mechanisms and Future Perspectives

2026 · Yile Liao, Yu Gui, et al. · The American Journal of Chinese Medicine

Works count: 4

Citation count: 3

H-index: 1

I10-index: